Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sad but true ...
Best to you and your son.
Grip, always good to see your thoughts. I don't disagree. Financials are a big risk with CYDY right now.
Missed the item about your dad. Sorry to hear that and hope he's recovered/recovering. GLTU.
Anemic volume. Takes me back to the days of 2017/2018, where there were plenty of days that the daily volume was less than the total shares I owned (and that says more about the daily volume than my share total)!
[Cheers theme song playing]
Thanks for the reply, ex. Nice to see some familiar faces around here.
Those who have been around here a LONG time may remember I used to post from time to time several years back.
I owned, sold out for a time, and got back in last fall. Candidly, I took some profits on the run-up to the current plateau and haven't followed closely since. I still own half my shares.
That said, what's the guess du jour on TLD date?
Thanks all and GLTAL.
Hard to disagree. The only reason I'm holding my remaining shares is to be able to vote them.
Painful and avoidable. I guess the silver lining is that there are now 3.1 million more shares that will be voting against current management.
Nailed it.
"He is the biggest pumper and then on the CCs he walks everything back to make it seem like he didn’t say it ... The amount of times he contradicts himself is outrageous."
Heaven help us all if they do!
I have seen elsewhere, but can not confirm, that it may have been as late as the 18th (given the last 3-4 patients enrolled beyond 390).
I can assure you that the statistical skills required for this discussion are not above my pay grade or that of many on this board, so please do us all a favor and show your work on your fourth point. Thanks in advance for enlightening all of us, as you'll be saving us all a lot of heartache (and money) if you are correct.
yes.
Good news DonDon. If the information is not good, as you claim, it will be reported within 4 business days of CYDY's receipt. So, if you're correct, you shouldn't have too long to wait.
FWIW, I agree with this response also. The efficacy of any therapy that acts indirectly to heal the patient (remdesivir (haha), dextramethasone, lenzilumab, leronlimab, etc.), rather than directly on the viral spike protein (e.g., Regeneron), should be unaffected by viral mutation.
(not a scientist but did stay at a Holiday Inn last night)
Interesting, and thanks for sharing. Certainly reinforces the need for therapeutics.
Question for the board: if the new variant's spike protein mutation results in it "partially escaping prior immunity" resulting from COVID-19 infection or antibody drugs, then wouldn't the new variant also "escape" any immunity acquired by vaccination to the same degree?
100% correct Blue Man.
The R/S issue is dead. CYDY has no authority to effect a R/S without further approval of the shareholders. Give it up.
I think you might be holding your chart upside down?
Very sorry to hear that and will keep you and yours in our prayers
What updates, if any, were provided yesterday regarding the status of the HIV combo BLA in the US? Thanks in advance.
Agreed 100% JLA, but that's never stopped them before! At this point, IMO, CYDY management just is what it is... GLTU
That's one reasonable view, albeit an optimistic one.
I'll be the first to admit that my views on CYDY are colored by the fact that I've been invested nearly 4 years, and logic like you are employing has failed me over and over during that time.
Regardless of that fact, I still have many reasons to hope you are right and I am wrong! GLTU
Indeed. If not a typo (and I maintain it almost certainly is not), this wasn't a new financing. It just kicked the can down the road a bit.
Agreed 100%
There are 2 notes, and the second note references the first.
CYDY owes Fife and his affiliates $50M+ currently.
RE: recent 8K, November 2020 $7.5M/month repayment.
I don't think it's a typo but would be happy to be wrong.
To be fair, this was also PR'd this AM. I agree though, the increase in trial size was buried and is, at best, neutral.
https://www.humanigen.com/press/Humanigen-Announces-Cooperative-Research-and-Development-Agreement-with-the-Department-of-Defense-to-Develop-Lenzilumab-for-COVID-19?utm_campaign=2c9a5d27-c185-4e58-a4de-3b497fa85002&utm_source=so&utm_medium=mail&cid=e4f865ab-19da-42a1-bdb1-0a896bcc5cff
Balanced post. So, on HGEN, are you adding or holding currently?
It seems like the only upcoming catalyst is enrollment (and hopefully data) by EOY - is this accurate?
Thanks in advance.
Grip, what are you eyeing as an entry point, or is it entirely situational?
Without any basis other than gut feeling, I was thinking $1.50.
Sad but true, Saltz. Great post. I agree with you completely.
What do we bet that CYDY is trying to raise capital right now? The Proactive video + PR combination - how often have we seen this in advance of a capital raise over the last few years?
Look who the cat dragged in. Good seeing you here, Grip.
I've been following NWBO off and on since 2017. Lurk here but rarely post.
Hope you scooped up a few shares in late August/early September!
Certainly going to be more interesting here than our other investment over the next few months, IMO.
CYDY, HGEN, and RLFTF all are down 5%+ today. Gilead news.
Please let us know the gist ... thanks.
Check off, or take a shot every time you hear one. The latter approach will be a guaranteed good time!
After all, they did move the call to 5:00 ....
On which date?
Amen.
Thanks, SmileyRiley. What is your take on the receptor occupancy test/BLA issue discussed today? It seems there is a lot swirling around the IncellDX/CYDY relationship and a lot of he said/he said going on ... any thoughts? NP made it seem today like BP screwed up the ROT data.